Evidence map›Paper›PMID 33187983›Full record

ArticleThe Journal of biological chemistry

Repurposing p97 inhibitors for chemical modulation of the bacterial ClpB-DnaK bichaperone system.

Przemyslaw Glaza, Chathurange B Ranaweera, Sunitha Shiva, Anuradha Roy, Brian V Geisbrecht, Frank J Schoenen, Michal Zolkiewski

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. OMICS and Other Advanced Technologies in Mycological Applications.Journal of fungi (Basel, Switzerland) · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. The Role of ClpB in Bacterial Stress Responses and Virulence.Frontiers in molecular biosciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Przemyslaw GlazaDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, Kansas, USA.
Chathurange B RanaweeraDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, Kansas, USA.
Sunitha ShivaDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, Kansas, USA.
Anuradha RoyHigh Throughput Screening Laboratory, University of Kansas, Lawrence, Kansas, USA; Lead Development and Optimization Shared Resource, University of Kansas Cancer Center, Kansas City, Kansas, USA.
Brian V GeisbrechtDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, Kansas, USA.
Frank J SchoenenLead Development and Optimization Shared Resource, University of Kansas Cancer Center, Kansas City, Kansas, USA; Higuchi Biosciences Center, University of Kansas, Lawrence, Kansas, USA.
Michal ZolkiewskiDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, Kansas, USA. Electronic address: michalz@ksu.edu.
Kansas State University · USThe University of Kansas Cancer Center · USUniversity of Kansas · US

Funding

Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI OROZCO, ROBIN C. · 2016 to 2025
$23.9M
Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogensR01AI141586 · NIAID · KANSAS STATE UNIVERSITY · PI ROY, ANURADHA, SCHOENEN, FRANK · 2019 to 2022
$1.9M
Novel Staphylococcal Inhibitors of Neutrophil Granule EnzymesR01GM121511 · NIGMS · KANSAS STATE UNIVERSITY · PI GEISBRECHT, BRIAN V · 2017 to 2020
$1.2M
High-throughput assays for inhibitors of the Hsp100 molecular chaperonesR56AI121366 · NIAID · KANSAS STATE UNIVERSITY · PI ZOLKIEWSKI, MICHAL · 2016 to 2016
$388k
NIAID NIH HHS R01 AI141586NIAID NIH HHS R56 AI121366NIGMS NIH HHS P20 GM113117NIGMS NIH HHS R01 GM121511
6 · The paper itself

Abstract

The ClpB-DnaK bichaperone system reactivates aggregated cellular proteins and is essential for survival of bacteria, fungi, protozoa, and plants under stress. AAA+ ATPase ClpB is a promising target for the development of antimicrobials because a loss of its activity is detrimental for survival of many pathogens and no apparent ClpB orthologs are found in metazoans. We investigated ClpB activity in the presence of several compounds that were previously described as inhibitor leads for the human AAA+ ATPase p97, an antitumor target. We discovered that N

Indexed as

Microbial ViabilityAdenosine TriphosphatasesBlotting, WesternDrug RepositioningEndopeptidase ClpEscherichia coliEscherichia coli ProteinsFluorescence PolarizationHeat-Shock ProteinsHSP70 Heat-Shock ProteinsMicroscopy, ConfocalSurface Plasmon ResonanceAdenosine TriphosphatasesClpB protein, E colidnaK protein, E coliEndopeptidase ClpEscherichia coli ProteinsHeat-Shock ProteinsHSP70 Heat-Shock ProteinsAAA+ ATPaseantimicrobial compoundClpBDnaKmolecular chaperoneprotein aggregationsmall-molecule inhibitor

Identifiers

PMID33187983
PMCPMC7948422
OpenAlexW3101388580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.